<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-014088
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>5
<PERIOD>20060406
<FILING-DATE>20060406
<DATE-OF-FILING-DATE-CHANGE>20060406
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06743740
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v039956_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: v-->
<!-- Document Created using EDGARIZER HTML 3.0.2.1 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of April 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">x</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;April
              6, 2006</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><em>Chief
              Financial Officer and Company
              Secretary</em></font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Positive
                European trial results for Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>TM</sup></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">&#160;</td>
            <td align="left" valign="top" width="62%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v039956_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.2.1 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="white">
              <td width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
                RELEASE&#160;</strong></font></td>
              <td width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>6
                  April 2006</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Positive
      European trial results for Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth,
      Australia and Boston, MA - Global bio-nanotech company pSivida Limited
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NASDAQ:PSDV,
      ASX:PSD, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      today
      announced that global eye health company Bausch &amp; Lomb </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NYSE:
      BOL)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      recently
      released two year results from their European clinical trial of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(TM)</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for the
      treatment of chronic non-infectious </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">posterior
      segment uveitis.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Bausch
&amp; Lomb, exclusive licensee of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(TM)</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      conducted the randomised study that showed the recurrence rate for uveitis
      was
      significantly lower in</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      eyes
      receiving Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(TM)</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      than in
      eyes receiving standard of care (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">systemic
      corticosteroid or other immunosuppressive agents)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      study involved 146 patients across ten countries in Europe and the Middle East.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      abstract (#1220) detailing this data is available on the website of the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">prestigious
      6</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      International Symposium on Ocular Pharmacology and Therapeutics in Berlin,
      that
      commenced on 30 March 2006. http://www.kenes.com/isopt/index.asp</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;<IMG SRC="finger.jpg">&nbsp;</font></td>
            <td width="75%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Uveitis
                is a leading cause of blindness affecting an estimated *200,000 persons
                in
                the EU. It is also estimated to affect ^175,000 people in the US
                and
                approximately ^800,000 people worldwide.<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                Uveitis is a chronic auto-immune disease in which the body&#8217;s own defences
                attack the inner lining of the eye (the uvea). </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(TM)</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                approved by the FDA in April 2005, is the only FDA approved drug
                for this
                disease. Retisert(TM) is surgically implanted into the eye and is
                approved
                to release a constant amount of the drug, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">fluocinolone
                acetonide</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                over a treatment eriod of 30 months.</font></font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Surgically
              implantable Retisert<font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font></em></font></td>
            <td width="75%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      receives royalties from sales of Retisert(TM) which is presently priced at
      US$18,250. Covered in the United States by Medicare and Medicaid, Retisert(TM)
      is co-marketed in the United States by Bausch &amp; Lomb and
      Novartis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;We
      believe a positive result such as this in a European study is an important
      step
      towards registration in Europe, enabling Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(TM)</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to be
      made available to a much wider market,&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      said Mr
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
      Rezos, CEO of pSivida Limited.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*Source:
      European Medicines Agency</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">^Source:
      Bausch &amp; Lomb</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="white">
              <td width="75%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>What
                  is Uveitis?</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
                  autoimmune condition, Uveitis manifests itself as an inflammation
                  inside
                  the eye, that can lead to sudden or gradual vision loss. </font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  is a global bio-nanotech company committed to the biomedical sector
                  and
                  the development of drug delivery products. Retisert(TM) is FDA
                  approved
                  for the treatment of uveitis. Vitrasert(R) is FDA approved for
                  the
                  treatment of AIDS-related CMV Retinitis. Bausch &amp; Lomb own the
                  trademarks; Vitrasert(R) and Retisert(TM). pSivida has licensed
                  the
                  technologies underlying both of these products to Bausch &amp; Lomb. The
                  technology underlying Medidur(TM), a treatment for diabetic macular
                  edema,
                  is licensed to Alimera Sciences and is in Phase III clinical
                  trials.</font></div>
              </td>
              <td width="25%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&nbsp;<IMG SRC="eyeball.jpg">&nbsp;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon(TM), which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon(TM). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      conducts its operations from offices and facilities near Boston in
      Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
      Singapore. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed from the UK
      Government's Defence Evaluation &amp; Research Agency (DERA).&#160;QinetiQ was
      instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with them. For more information visit
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties.&#160; The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases.&#160;
Although we believe that the expectations reflected in such forward-looking
      statements are reasonable at this time, we can give no assurance that such
      expectations will prove to be correct. Given these uncertainties, readers are
      cautioned not to place undue reliance on such forward-looking statements. Actual
      results could differ materially from those anticipated in these forward-looking
      statements due to many important factors including: the failure of Retisert
      to
      be registered in Europe; failure of the results of the Retisert for DME trial
      to
      be a good indicator </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
      the
      results of pSivida&#8217;s ongoing Phase III</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Medidur(TM) for DME trial; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(TM)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      in DME to show a very similar improvement in visual acuity and diabetic
      retinopathy severity score as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(TM)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      DME</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
      inability to recruit patients for the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
      III</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Medidur(TM) for DME trial; our failure to develop applications for
      BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
      expected revenues and the combined entity&#8217;s inability to develop existing or
      proposed products; the failure of the Bausch &amp; Lomb/Novartis co-promotion
      arrangement to provide faster royalty growth; failure of the slower progression
      or reduction of diabetic retinopathy resulting from the Retisert(TM) implant
      to
      have significant implications for Retisert(TM) and Medidur; failure of our
      evaluation agreements to result in license agreements; failure of Medidur(TM)
      to
      release the same drug as Retisert(TM) at the same rate; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(TM)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      in DME to show a very similar stabilization or improvement diabetic retinopathy
      as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(TM)</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for DME.
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      reasons are contained in cautionary statements in the Registration Statement
      on
      Form 20-F filed with the U.S. Securities and Exchange Commission, including,
      without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake
      to update any oral or written forward-looking statements that may be made by
      or
      on behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>eyeball.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 eyeball.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_
MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L
M(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)"0P+#!@-#1@R(1PA,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C+_P``1"`"6`,(#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`H/2BB@"I<:E9VMR+>>=8Y#"\X#`@;$
MQO.>G&X?G4-MKVEW3[([V,2;%?9)E&"LQ520V",E2!]*BUW08==@@BEE:+RY
M,LRC)>,C#QGT#*2#68?!5NVIB[>Z++YS3%#$,Y+S,,-VQYY_[Y!H`Z`:A9%0
MPO+?:9/*!\P8W_W>O7VITE]:1)ODN847(&6<`<G`_4'\JXE_`<6F:3*WVR68
M1P-&X$)D9HMBH=H=SB3"<,/RJ=O`J7EF0FK%HV5?LT@A^:-<RL#D,,M^^//`
M('(.3D`[%[F".6.*2:-))/N(S`%OH.]0IJ=E+=16\5S')+*'*!#N!V%0W(X&
M-R\>]<YX@\.WFI:K:M$$,#)#'/,VW<@CDWY48RK'D9'MTQFK&@^$(]#N8)UN
MVE:)'CQM/S`K&H)W,QR!$.G'/08H`Z:BFOG:<=:R+G78;*41W68\G`DQE,^_
M]W\:`-FBL<>(+2.4)<D19QA\_*?QK65U=0RD%2,@@Y!H`=1110`4444`%%%%
M`!1110`4444`%%%%`!136=44LS!5`R23C%`D5@"&!!Z$<YH`=13=Z\\].OM2
M[AZT`+12;AZT;AZT`##(-9&DG[!=7&D$G;'^^ML_\\6/W?\`@+9'T*UL$X&:
MQ-?F%O\`9KJW#27MLQ=88QEI(\8=?88YY[JO?%`&R`#SWJE)JUJH;RW:<I]X
M0C<!]3T'XD5S]WJ@N83,)8;F/&6W2%;:)2,Y;."_!'7@]A69<7S&-9FD$=N!
MA9;I>.W^KB&/3J<?2@#HI?$6)#$L<8DP"$#&5\'ID1@C/_`JIZC.+U"ETH/8
M,MG(K#Z$L#^E<?=>)8U4Q0B:=3_SU?8A_P"`)A:R9-6E?.+>U0>@B%`&_/HV
MJK$Z6NIQRVK,0([NSD0+[[USMSVX^HK3\.)K.F6&8)HV3><PRR!X#Z[)%^[]
M#CZ5Q2ZC*C!EBB5A_%%E"/Q7%:FG>*[RTD^:=FS]Y)SDGZ..<_[V10!ZI:ZA
MYY$<T+VUQ_SRDQS_`+I'!%7:Y;0_$4&O0M;W4:QS)\^`^<K_`'U8>G?N/IS6
MVLKVA`G??!_#-Z?[V./QZ>ON`7J*0$&EH`#TK,O==LM/O1:W<ODDQB02,/E.
M7"!?J688%6=0OHK"RDN)`S%<!(U'S2,>%4>Y/%9<?A\74EO>:C+(]ZA5VV-A
M%(D$@4<?=!`'T^M`%RQUNQU$HD%PAF9`_E@@E1@'!(R,X(/7H:TJP-,\*6.D
MWL5U;27&Z.`0!688*@`?,0`6Z=R0.V*WZ`"BBB@`HHHH`Q/$=C-?6EJ([87<
M4-TLT]FS!1<(`PV\\$ABK@'@E`"1G-<[:6&N0:D+>WAN;.T>1;B.%)4$%M&T
MIWHV.K%`2`I(4M]#7>;0:3('M0!P^F:7XBLOLD;BY,"B,;$N8PX98X5+2,0=
MR_++ZGD<="MG5+#Q.]UJ$^GWDB[W801M(NU8_+CQA2/O%Q)SGOUQTZV2,LOR
MM@UE7>KQV9"W@\H_\]`.![Y]*`,*&Q\5QV3W274DEU"J_9K::50DG[Q\K)C=
M\VPISD\CJ>2;FC6/B"U\07']HWDEQ8B,JCMMVO\`=V$#.0V`^?E`R>IXQ;&I
M2QW`PJ[I/N<XCF'L?X6_0_RN'47F79:VLYN3P%FB953W9NA'T))[4`27M\R-
M]G@V>>5WNS_<A7^\WY'`[X[#)'/7LZ1V\ID:2*#<K33NN9;DGH@7W[*.``.U
M3R!-Q4R_Z-;LTDLT@&)I`/F=L?PJ.W<X':N3U?669Q<896((M8B<F)#UD;_;
M;K[#B@!E[J4=C"L;IOEB<M!:%MT=L&)QN_O,.GL,`5SMU>7-]-YEQ*SL?7H*
M9D^9YK9((PX'.5/7^A_`>]/\HABN,D=_6@"()QQ3Q'FK*6Q)'%6X[3VYH`SA
M!FE:UW#&*V$M..E2"U'I0!D6$\]A=)Y<K1,&S%*O_+-B/Y'H1[UZIIFL)=Z=
M'<[,1.-LL1Y\MAPP]Q_0BO.[JS!CSCITKJ?!D7SWL4DHWML9$SR2HPS?3YE'
MU%`'6V["VD6#.89.86].^W_#V^E6]W(XZUS\6JVMQ?P::LB>3<Q-)">4D5D/
M/#`<=QCT/&.:=/>2:FZZ3%(`TB[KF:/C$'3Y?0OT'I\Q]*`)K0#5]1_M!B#9
MV[,MH,\._1I?<=57VR>XK9`Q38HHX8DCB0)&BA551@``8``J*^O8=.LI;NYD
M\N"%2SM@G`]@.I]J`+%%9$/B&S>/==>;I[^8(A'>J(V+$`C'.&X(Z$XZ'!!%
M3+KFF/<K;KJ-H9F<QK'YHW%AP5QZYXH`T:*S1KNEF-)1J-KY;OY:MYHP6QG'
MZC\QZBM$=.:`%HHHH`*K7<,LD>8&`D'9ONM[&K-%`'.IJT]O-Y,\3+)C_4,0
M&QZHW1A[?KQBK$_V36;)XW1+F,'#+]R1#Z8ZJ:T[JS@O8C%<1+(A[,.GT]*P
M+K0+JW<36%PSLOW=S[9%]@_1A[-Q0!SNIV=WHMC,L5RMWIJ\^7,FV:WQ[=UZ
M<C!&.C5TFE3W<.B:?+?W)\^15^\",YR1D=SCK_NDUCMKDB:C%9ZQ:I)EE59)
M(]K*Q.`6'0C)`R.*W+ZR:]"1W$C1N!LC\MR&7<<%N#]/RH`YWQ!<)8VD>G@L
MX/[^X5N"%SE(R.V6);';&*XV5Y+B=Y96+,QSFKEUO<1@LQW*&=F.69NA)/>F
M1PEB.*`*Z0G.<58AB"D1M@$$!,_Q`]/RZ?E5R*V/'%/FT5;FYM;E6*302*P/
M9AGD$?3O0`^*UW8XXJ[':_[//\ZO16F!P*MI;9'2@#-6U!I_V4>E:HMAFI!!
MQVH`Q)+7Y#QVJ&SO9-!NGO4@61VA\M@<C."".?S'Y5T!MQTQUJ&#2HKV5Q<(
M6@A^4J"1YC]2..PX_.@#GIYGU2T:XN)Y);BTN`L,P79*5.2AXZ'.Y<CUY[UN
M>'9BT[VURJIJ88RQ7&<B88`*\]@!C'H,]0:K_P!C0:;K-S!%O:&XMC-`A^8H
MZ<D*3SR,C\:OPVJWEG!<1G9,F&1Q_"PZ'Z?T-`&J-::[`33+9KJ7.';=MAB/
M<&3!SCT4'\*;+H<E_:SIJE[-.\R%"L),4<>?[JY.2"!RV:FTZ8%HBJ"-95VM
M&.!'*O!`'N,_E[UJT`<W<>%&O4/VS5[V>5U>*21E3F)U"L@7;A<[0<@9SFG?
M\(A8[`F^;:,#J.@F,OIGECCZ>_-=%10!QB?#NR6Q%J+VZ6//S[`J[U"JJ[@!
M@D!1@G/4_AV2C`P:6B@`HHHH`1B%&2<4`Y)&>1VK&\5Z5-KGARXTZ`D/,\0W
M!MI51(I8@^H`)KE)]$\6AKZ]@)BOKU(R[0SCY'C214&"0-N2A/U.0PH`]%IH
MP:XR6W\5QI-)']IDN&,H?%Q'Y9)601F-3]T*3'G..G0\DD&F^)K?7+1HV9;)
M9R\P$JE)%9I"V1V/,>.#]1@@@&YXFTB+5M$N(=BF=(V:%CV;'3Z'H:KR.TNL
MV\CNY\N!61<8'S`Y/OT'TS5IKG65RLNDP2*01F"\R?R95_G7/G53:26=[=6-
MY'"EH@=]JL/E8`G`8_WC^=`''"2;^T8[2:.,(]NLL#H22P&`P;/<%NW:M&.V
M]!^/K5'4IHK:33[_`&S"*V)AFW0LK!)/E4C(&?F"<"NCB@Z#'M0!%#:?+GFM
M*"VXY_'VJ2.+`Q^%75B`*\<^U`"1P8`(Y%3K#Z"G",HO&,CN.#4BH2`2QS[&
M@!GDCTI?*QVJ8''!_.EZT`5R@4%CT`S4FG1F/38&(^>0>:WU8Y_K^E)<*6MY
M`.I0@?E3K)Q)IEHXZ&!#^@H`Q/%5RVG16.H*`3%(\;'T5E.3^'7\*LZ*V?M,
M8V[5D!4#HH*C`_0U4\:L/[%6,[29)2JAAD'*$8_7%)HMGJ""=3>)&0ZJ?W(;
M/'7.:`-L#RKF8XP-T4P]B3M)_(5L"N:N8[Y!,3J"'$:Y_P!&'=\`?>]<UJ?9
M-3R?^)HG_@,/\:`-!W"*S,P55&22<`"H+2^M;Y#):74-Q&#@M#('`/X50O-.
MU*YL;JW;4(Y!+`\>PP!025(&3DXY/I7/3^$M6LM.3^RKW??26S6\[S3>2HS$
M41AY:<[6.>F><YS0!VLTT<"AI94C7U=@!TSW]@?RIZG(S7GQ\-Z]J,5T6<P+
M)+<!EGNG?S@?."$J1A``R#`X(^@KOX5*0HK8R%`XH`?1110`4444`%%%%`"$
MXKF;]&ALY%PKQP3O%*CL-ICDPPR#UZJ*Z>L;4K9'NI(6X6\AV@`=9$RP_'&>
MX^[UH`XOQ)`EK;C:2T-K>VTR$\D1LZ]?7&?TK6A3#8/6J^IVD6KQVJS>=%$2
MJ21H2NXQG>BMGDKU_P"^*N0\M[]Z`+L29(QP<5;$05>!^-1P+\OK5L+DCTH`
M1?UH`VGCZ_A2[2#P>.U./K0`G44M)[]J,T`-)P*I6$K1Q7-D@7S+=B8PY(!5
MB2O([9R*MR'`K`U2X:W)N8I3'+'N`91GCN".XX%`#-0O$O-;L;2_C-IY,<LD
MJLZG)*D+L(^]G/'?CI6EH),MGYQ4@NV2/<`"N4LDDE?5+N\W33W#);,70<=6
M(V]@`H_.NA@M+RW@2UM)S(?*W30SO\J#OMDY*9.0,Y'!Z8H`TB?M$D1!R+JX
M0KCO'&=V?H3G\"*WAQ7/:;J%O<ZJOG`VLJQA8+>4;<@]U/1N/0]^@KH10`M%
M%%`!1110`4444`%%%%`!1110`5GZO:O=61\D#[3"PF@/^VO(_,9'T-:%)CF@
M#D+R.*Y9;^*01Q7Z#DK_`*N93E<^N#D>XW>U,A?S!N*E'#%)4/5'!P1^=7KZ
M!+"XF27<-/O#N9E',3C^(?S/L/8YHW6;2Y,C*OF@*CH",3+_``[/5P.0.I''
M)%`&I;MD#FKZ@%:Q[6>.2))8I`\3_=85HQ3`]Z`+!6FD4Y9`12EN*`&8IIX%
M*S"H)'Z\T`,GDP*J:7!]KU27S88I($B(8-@X)*D9!]<'GV-,O),IMSR>WK2:
M'(V;J[3'ER;8XV]57/(^K,?RH`S+G2IEO8;*W1K9I"\Y+2^9(6W?ZQA]`N!C
M'&/6M2SN<V,L<T/EF"013Q!]S3S<=3UVGC&?7'`%:1E:'=,$C^US+M3(Y5`>
MK'N!G/U/%926SQ2+K<,8DCMCL:/&6EB&=SCU8$DC_@0_B&`#>738IK#[/>Q1
MS[SOE#+D%CW'I[5D:UI6I0Z%?P:==3SQM`PBMV.Z56[!)"0?P;/U%=%%,DT2
M2QL'C<!E8'A@>A%24`<9J%YXHNM2273H+NUM6B'EPR0QG+#?O\S)R#_J]N#C
MZ\BF(/%MOJ5HCSW=S;B==Y,<(WJ4B+;F`XPQEP`HR!UR!GMJ*`$%+110`444
M4`%%%%`%/4]1BTK3Y[VX#F*$98(,D\XP/SJC;>)]-F#>;.MHZS_9S'<LJMYF
MU6P.2#PR]#WJ[JNFPZMIT]C<;O)F`5MN.0"#WSZ5AS^!]-DE!B:6"$2NX@14
M,:A]I=5!4X!9`?8EL=>`"]%XKT62W%P=1MXX2VQ7E<(&8%@0,\\;35K^V]-S
M<C^T+7-J<3@RC]WSCG\>/J,5E-X,LI(Y%DFN6\Q)8^2O"R*ZD=.P<X^@S5C2
M_#-OIFHSWHGN)Y)5VXF*D*-Y<=LD@GCV`H`6>:ZUB,Q6EJ8;9N?M5TA!]04C
MX)^K;1]:Q9-*%C,JW!EDD09CN@-SH`"/D'3;SR@`P<$9XKMZAN;:*ZB\N5<C
M.00<%3Z@]C0!Q4]O=6BB^AFA1I%#2N#FVN3ZDCE&_P!K'/<=ZE35E38+B-K9
MV'RB0Y5O]UQP:T;BPN;!WD20A'SND5`4;_KHG3\1^8JI);I(GF/;2(K8R]F^
M^,CWC8X[]MU`%J.^!`^;K[U/]K7'6N;.GP,X:&ZMK;/7;.\&#_NLI'/H!^-.
M-O=QC"Z@K]N1&WZAQ0!T)N<CK4$]W'%&7E=44=2QQ7.RRB-,W&LQPK_%N:.,
M`9QURQSWZ?C5W13H%W<9,\TDO427"L`?]TL`,=.0!0`R-FUVY,<32)9(=LTP
M&-W^PN>I.1SV%=&@(DV+$I90`L6,+&.Q;T]AWJ0,C+NB!AA7@S-]X_[H/3ZG
M\N]01O+>+Y.FIY<`/S3L./P_O'_)-`#9(WN[AK.*1B[@&YGZ%1_3/8?4_7=B
MBCBB2.)0B(`JJO0`=JCLK2*R@$40.,Y+-RS'U)[FK%`&+:?\2C4?L+?+97+%
MK3CB-^K1?0\LO_`AV`K9!JM?V27]E);R%EW`%70X9&'(8'U!P:YV[UW5M/OK
M.UEMX))Y845DW%5,C3+'OW`$@8);&/:@#K**Y+P_XM?5;^WLIH51I+59E<OE
MF.`3D*,+UZ''3(SFNMH`****`"BBB@`HHHH`****`"BBB@`HHHH`*I2Z9`[E
MX]T#L<LT7&X^I'0U=HH`QY]-?8?,>"0>KJ5/XXSG\JR)M%BF)_T:&(?\]#AO
MR7`S^.*Z>9AZGZ"J<@+?*%))[#O0!R[Z5#`V+:!#)_SWE`.WZ`<?D*N:79KY
MY\J$74XY,TGW5_'''TK832&FDW7#X3^XAY/U/^%:D4,<$8CB0(@Z!1B@"BFE
M+(V^\D\\_P!S&U!^'?\`&M!4"@````8`':G=**`"BBB@`(R,4W9DY(!-.HH`
MC$2A]P50V,9QSBI***`"BBB@`HHHH`****`"BBB@`HHHH`****`"@]***`&[
I%]!2A0HX`%%%`"T444`%%%%`!1110`4444`%%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>finger.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 finger.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_
MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L
M(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)"0P+#!@-#1@R(1PA,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C+_P``1"`!Y`*L#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#Q%F;>WS'KZT;F_O'\Z0_?;ZTO2L3H%#-_>/YT
MNYA_$?SI*6@!0S?WC^=+EO[Q_.DI>E2,4,?[Q_.ER?[Q_.DJ:"WFN91%#&TD
MC=%49-`R++?WC^=&6_O'\Z[O1?AQ=70634)?)4\^6G+?B:[:Q\`Z-;*,V:R$
M=W^:LW4BBU!L\/\`F_O'\Z,-_>/YU]"Q^%M+08%C;X_ZYBJ]SX+T>Y7$EA#C
MU5<?RI>U\@=/S/`?F_O'\Z0[O[Q_.O6M1^%MF^YK.>6%O[K?,*Y+4?`&LV(+
M1QK<H/[AY_*K51,EP9R!W?WC^=-.[^\?SJU/;RV\ICFC>-QU5EP:B*UI<SY2
M#+?WC^=*-W]X_G4FVDQ34B;"`M_>/YT]2?[Q_.DVT\>U%Q6%#-_>/YU9C9O+
M'S'\ZKBK,0_=C\:+A8S6^\WU-`H/WF^II:1H+0*,4HI#%%+12BD,MZ;IT^IW
MJ6T"Y9CR>RCU->R>&_"]II,`\N/=*1\TC#DUB^!M#%C9+/*O[Z;#,2.@["O1
MK:,!!GKVKFJ3<G9&T8V5Q8;85>2$=@?Q%$29QC@59''0$GM22!LC$0`_G_G_
M`/52,,=>M6=HVYSCO32F1^&*H5RF\6\=.:KR6ZMG*UH[,_@/\_YXIIR/?ZFD
M.YS.J>&['4HREW:I(/4CD?C7GFN?#*6+,NER[AU\J0_R->S%`W#!@/85#):!
ML\\^U--K8'9[GS)>Z;=Z?,8KNWDA<=F'7Z&JVVOH[4-&M[N(QW$$<J'LR@UP
M6M?#>"3=+IK^2_7RVY7_`.M5JIW(=/L>78]J4+6CJ6BWVE2;+RW9!GA\94_C
M5'%:7,[#<58B'[L?C4-3Q?ZL?C1<FQF'[S?6E[4'[[?4T510M+24M(!:T-%M
M!?:Q;0'[I;+?0<UG"NC\%H&US<?X4/\`.ID[*Y4=6>P:9`$B4\5O6_5<^W]*
MQ+)L)CJ*VK<@L!Z$?S%<L3JDC0A(5<D=L_IFIE'S`=<#'7K_`))JK$V8^_W>
MGX+_`$J5<D8_+]:T,K$^X$^WK_G_`#S2\`9/Y>E8>K782[LK620QP3OB5@<?
M+D#\N<_@*Z36;&PTK07EMECAD3:8F3@N<CKZYJ5*_-Y!*/+RK^8K=3CN*78"
M.AJA8:E#>@Q*RB=/OQ'K]1ZYK10`X]?4=Z<9*6J'*+B[,C"#KC_QVC9P#C*C
MJ?3\O\:FQE<D]/\`/>FL0,`KR>A/^?Y'\*NQ)4DC!!/'I5*:V&>GZ5LG#`'\
M,CU]/_K<?2HFB#*01^0QS_GMQ0XC4K'+7^F074+1S1(Z-U5AD5YOX@\`O$6N
M-*R1U,#'^1_I7LTELI4Y!'/6LV>U'.:B[CL7[LMSYREAD@E,<J,CCJK#!I\7
M^K'XU['KWA6TU>(F1-LF/EE4<@_UK@)?!6J0RO&B+(JDX;=C(K133,I0:.(;
MEF^M%-;[S?6C-;&(^@4W-+0`M=#X/F\O6<?WD_K7.BKVE7/V34X)B>`V#]#2
MDKJQ479GNMA+NC4?Y[5JVDK%U+#!W`?KG_"N7TB[$D28(YXKH(I0Q)SQSC\>
MG\JY=CKW1M0M\A/^SC_QW_ZU65;+>F&_J:H0,..>#_C_`/7JU$^,'\3^8-40
MRKJFG1:A;[7'S(,JP[':*P+NWU6V4ED-U'%N"_/V'^S_`/7KK#C&WU']"/Z4
MK*K@X'8_T-95*2GZFU*NX:-71YO'<23S2W#RO'=AQM15(+<XXQT/M7I>F)=)
M8JEXP>=,AR,'GT]R.A/2J$^BVLUXMWLV2QMO#J<'(;(_I6ZF`&`4<%C@]^X_
MQK+"X:5.;;9IC,1&JERH8!@^GOGC]*79R??J,9S^'?\`G4C8)+;CQZ_>QZ^_
MTJ,?(,@_7!Z>GX?RKNL<(W&/RZD]OKZ?7_Z]&!G@8'3'^?\`/UI6;G/?J?\`
M&FYV_3V[?YZ_F*`&NA(/!/OC_/\`G\*H30#/&*T2>,;1GMZ>G_UOH:@D7C*]
M_;_/M^52T5%F:8ASQ^-5_LZGT%:+1]#T_P`__JIGEKZ"HLB[GRBQ^=OK10WW
MF^IHKK.,44M)2T#%IPIHIP-(#O?"NL%X%C=OG3@Y-=]9W6\@9R/Z?Y->'Z?>
M-972RKTZ,/45Z;HVHJZ(0V01USVK&<>IT4I]#O8)MH'^?\]*T%E!S^./U'^%
M8-I<!U!R<_S[_P"-:,<F!SGU_D:S-&KFDDG)())Z\_G_`#S4R-@]<XQ_+_`_
MI5"$C``/(XS_`)]_YU9!P00/P_I^>::$R\I&S;CGD=>U3QN`_/3)_'M5%)<C
MG&!4JL=W`)'48'I[U29#1:!.`=V,<9_/_#-+QP0O?[OL>WY_SJ#?A#@YX/X\
M8_F33C*2SD'!&X_E@Y_.K)L2;1_O?U__`%C^5!&,]\?KCD?I3=RJ3CH,G\!S
M_(TI?!^A&>W8?XT@&;>P/']/\D?E2$AO4'.,'\OZG\J4?=(//`R/P_\`K"HG
M<;OQR#^?_P!>DQHA<<%CW/3TR.*9Y>>>/RI[<'GHHYS[<"F$G)P/;@5(SY,/
MWV^M%*WWF^M*`372<PE+3@A/:GB$FE8+C`*<`3VJ=+<GM5B.V/I3L)R2*BQ$
MUOZ'>M:L(G)"D_*?3VJM':'TJY'9^U/EN0ZR6QW^EZEE1EN0:Z*UN@X`/;'^
M%>96LTUMAN2HZUTMAJ0D48:N>I3<6=E&M&HCNHI,XQW'0]^W]!5A9.ASGZ_Y
M_P`FL&SNU8*-PSCOT_S_`(UJK."`>N?UK,V9>CFR<Y/\O\FIUE`X.,?C6:CG
M'7)_S_G_``J;S",]>./\_P#UZ=Q-%_S,?-@D<'Z^V/2GA_E&.<#'UQR?U-4!
M+CN:?YF>".!_G`JKBY2\C9R.3D$?7.%_I3RX?/3YB2/Q(_PJEYI`"DXYY/\`
MGT%.#[F')P!C/IZ?IDT7)Y2SNR'8-_GD_P"%1,,+MQ@A<?7C']:(W^4!N,G)
M'UY_D/UH=B3NXSG.?IU/Z_I0);C<@G/.2<Y/Z?XT`M@;<X[5&S<\Y'MG]*0.
MN/F5B?84AV/E?R"6/'>ITMSZ5?6VRQX[U:CM/:NU0/-E62,Y+4^E3I:9[5JQ
MV@]*LI:CTJE`PE7,N.S]JM1V?M6BEL/2K"0>U6J9E*L48[3VJW';8'2K:0@5
M,L8JU`Q=5LK+`!VJ&6"6T;SH03'_`!*.WTK3"BG@42I*2LQT\1*G+F0FG:L!
M@$_Y_P`_RKIK._63^+KUKB+NQ>)C/:CW:/U^E2:?JP!'S>QKSJE%Q9[N'Q4*
MJT/0TN-N"*L+.K<'`QQ7-VVH+*H(;_/%7XKG(!SZ5C8[$D]3;5O04Y7Z]O2J
M44XVX[&I!(>3WH%8M%MIQW[8J6,@]2<?Q?Y_2J*MSR3Z<5+'(=PY_.A,36AH
M`G^(G`^\1_3WZ"GYR.0#C&0/7L*I^9C&#R/N_7UJ19/0]1A>?S-60T2,..H]
M`3^I_"HMWIM`]Z>SAEX'';/M_G-,QGD$8/KP:EL1X2D`W'CO5J.'%3+U/U_K
M5A>E>ND?-RDR%(ABIUB%3)UJ5:I(R;9"(P*D"@5,O2EJ[$W(A3LCUJ2E%`#`
M:7-/[THH"PRLV_TL3$SVY"3]QV?_`.O6O14RBI*S-(3E!\T6<W9ZG)!(8Y,K
M(O53U%=)8ZIDX)YS7,ZW_P`A8?[HK1L?NC\:\RI!)GT.'JN<4V=I!>;EZYJT
MEP"`1BL6S_U8_P!T5HP]&KGL=J+Z3#UJ3S!U!JLGWOSJ<?<'TH&TB=90PP2/
I<U*),G/;O]*JC[]68_X:$R&B02\=.30&!_AW>]-/3\:='_JQ18@__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!8`2<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`ILDB0Q/+*ZI&@+,S'`4#J2>PKE_$WC[2O#LGV-`]_JK$+'
M8VWS-N/0,1G;GCCEN1@&N>B\*>)/&TJ7?B^[:QT[(>/2K8XSZ;^N#P.N3R<;
M*=C&5;7E@KO^MS4O_B59->-8>';"YUZ]'WA:@B)><9+X/'N`5]ZS-2\0_$G3
MK"74Y]%TF&U@!>2+<7=4'4DB3!Q[?E7?:9I5AHUDEGIUK%;6Z_P1C&3ZD]2>
M.IY-<M\3M9_L_P`+-IL"F6_U5OLL$*C+,"0&P._!"_5EIJUS.HIJ#E*5O0W?
M"VOQ^)O#UMJD<1A,N5>(G.QU)!&>XXX/H1TZ5L5C^%M%'A[PS8:7D%X8\RL#
MD&1B6<CVW$X]L5L5+.B'-RKFW"BBB@H****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`J:C/<V]L'M(1-)N`*D9X]:S5U
MZ:WD1-0LFA5^CC/\JW:Y?4]/??<M'I\@`)<2_:!CU)V_GQ7C9I+$T?WU"3]+
M76GHF]?5>II#E>C.G1UD171@RL,@@Y!%8<OB5(G*M:2C!(R3C-'ABX,EI+;D
MD^4P*^P/;\P?SJ_K(!TBYR,_)_6JEB:N)P2Q-"7+HV]+[=/O062ERLSO^$IA
M_P"?63_OH56O]835;-[1/M]L'X:2TD"R`>S8)'U'-8-=KH0`T:WQZ'_T(UXV
M59ACL=6=-U+65_A3ZHNI"$5L9WA[P9H7A59)K.#,Y!+W5PP:3'4C/11ZXQG'
M.:F?7Y9Y733[-YPO5SG^5+XFN3%8I`IP9FY]U'/\\5GZ;I[G[.\FGNRLRL9?
MM``QG(.WZ=J]''XZO+%+#4-+?$TKO79;2MWO;[C.G3A"&QL1:FUOI5S?ZLJV
MD5N&=V((`0`$G^=<WX<T:YUS7F\8ZU$\<C+LTRS<8-O#SAF']]@2<=LGV"]-
M>Z8-3NXOM?S6<#"18/X99!R&<=PIY`Z9YZA<:->Y2@X046[ONS&4>>5WL@HH
MHJRPHHHH`*;)(D2%Y'5$'5F.`*=7':]>O<W[P[CY,)VA?5NY_I7GYEF$<#1]
MHU=O1(N$.9V-]M>TU6P;G/T1B/Y5:M;ZUO`?L\RN1R1T(_`\URMGH-U>6PG#
M1QJWW`^<G_`52DCN-/O"I)CGB/!!_45X7]N8ZBHU<127(^UU^K_X)I[*+T3U
M._JCJ6J1Z:(S)&[^9G&W'&/_`-=.TR]%_81SG`?[K@=F'^<_C3-2TN/4A$'D
M=/+SC;CG/_ZJ^@KU:M7"^TPFLFDU_7H9))2M(73=4CU(2&.-T\O&=V.<_P#Z
MJO50TW2X]-$@21W\S&=V.,?_`*ZOUI@_;^QC]8^/K]_^02M?0****Z20KSS4
M_B[I>EZI>6$FF7SO:S/"S+LPQ4D9'S=.*]#KSK5/A#INJ:K>7\FJ7B/=3/,R
MJJ84L2<#CWJHVZG/B/;67LMSO[.Y6\LH+I%*K-&L@5NH!&>?SJ:H+.V6SL;>
MU5BRPQK&&/4@#&?TJ>I-U>VH5SL_COPO;32PS:S;))$S(ZG.58'!'3U%=%7R
MMXD_Y&'6?^ORX_\`1C548W.7%XB5!)I;GU2""`1T-%-C_P!6OT%.J3K"BBB@
M`HHHH`****`"N;U*SC:_F/V&!RQ!WM=;">!SMS725DZM9[G%PL-D0!B1[@E<
M>G(->=FE'VM#:]G?I^J?Y%P=F8.EZK;:-:ZA?W;.(((/,?8NXG![#\?UK'T+
M5-?\4W&H>(;N+[)H@M'M[.WW'YV+H2_^U]PC=TYP.]:;106\TD=TMM=6=PC1
M3112!P4;JOKZ?XUT%[>V$FB2Q6LT(41[4C4A<`=`%[5Y&6XBG#+ZF'F[3BI:
M/SUT"K3E*JI7T.2KMM#_`.0-;?0_S-<376Z5?VEMHT`FN(T90<KN^;J>W6O,
MX;J0AB9RF[+EZ^J-ZRNBEXJ;,MJOHKG\\?X4FFV<?VNW/V&!6!!\P718Y`SG
M;FJ=Y.=8U$R!X8HU`5?.D"<#_'VK;TFSQ+]I:&Q"X^1[<ELGH><XKLH1^N9A
M.M%7BVK.RV775/MY$OW86-BBBBOKSG"O%_BUK.JZ?XOMX;'5+ZUB-A&QCM[E
MXU+>9(,X4@9X'/L*]HKPKXS?\CK;?]@Z/_T9+5PW./'MJBVAEGJOCGQ7H-OI
MNBK?26]JI6YNOM&UYW)+8,KL#@`@;0>G)X(`YFRUK7O"NLL8KFXM[JWE(F@E
M<E'(/*NN<,#Z_B#T->T?"?\`Y)_:?]=9O_0S7F/Q5A6+X@7K+UECB=OKL"_R
M4547K8X:].4:,:W,[Z'O&DZC%J^D6>HP@K'=0I*JDY*[AG!]QTKD=6@:WU2X
M5@?F<N#ZACG_`#]*O?#.0R?#S26;J%D7KV$CC^E=!J&FP:C#LD&UU^XXZK_]
M;VKQ,YR^6-H\L'[T7=>?D>WAZONJ3ZHS-&UN`6T=K<L(G0;5<_=8=N>QK5GT
M^TNIUGFA61U7:"W(QUZ=#7(W^D75AEG3?%_ST3I^/I3M.U>XT]@H)D@[QD]/
MIZ5XN&S:5"V%S&GHK:M?===?5?B;NG?WH,[1(TB0)&BHHZ!1@5A^)9YH%MO)
MFDCR6SL<KGIZ5M03QW,"31-N1QD&L'Q5]RU^K?TKVLXG;+YRIOM:WJC.G\>I
M)X:GFG6Y\Z:23!7&]RV.OK7F_P`6+K6='\36\]EJVHVUK>6X(2*[D1`ZG#8`
M(`X*'ZDUZ)X5^Y=?5?ZUSGQCTS[5X4@U!5&^QN%+-Z(_RD?]];/RJ\BDY8*F
MY.^_YLY<PBW3ER]#3^%^L3:QX+B:YGEN+FWFD@EEE<LS'.X9)Y/RNH_"N`^*
M'B;4XO&DMGI^IWUI%:P1QNEO</&K.1O)PI&3AE'X5?\`@GJ.V\U73&;[\:7$
M:_[IVL?_`!Y/RK@-0ED\3^+KAX&R^HWQ6$GL'?"?D"/RKV$O>9YM6O*6&@D]
M7^A[S\/([Q?!-A/?W5S<W-T#.TEQ,TAVL?DP6).-NWCW->,^*?$6NV_BO688
M=<U2**.]F5$2\D55`<X``;`%?1-O;Q6EK%;0J%BB01HH[*!@"OF3Q=_R.&N?
M]?T__H9I0U;-,?S4Z4$F?2>C.\FAZ>\CL[M;1EF8Y).T<D]S7D/Q3\8Z@^O2
M:'8W4MO:VH43&%RIE=E!P2#G:`0,>N<YXQZYH?\`R`--_P"O6+_T`5\X^,F+
M>--;)))^V2CGV8TH*[+Q]24:*2>YM^%[?Q[IUFFMZ);W<MB<L8V<.DH!Y_=%
MMQY'51GT-<?J=T;Z]O;QD"&XEDF*`YVEB3C]:^G_``[$L'AC285^['9PJ/H$
M`KYI\2?\C%K/_7[<?^C&JXN[9R8JA[*G"S;/J>/_`%:_05X3XW^).I:IJ4]I
MI%Y)9Z9"Y59('V//C^,L.0OH`1QU]![JHW0@9(RN.#BN-7X;>#-**7SVGDI:
MLLOF37;[%VG(+;FQCCOQ6<6EN>EB:=6I%1@[=SQJZT?Q3IMF-6N;74[>$X_T
MAF8%?3=SE>W7':N[^&/CS4+K5H]!U:X>Z696^S3R'=(K*"Q5FZL"`3D\Y&.<
M\:OC+XE>'9-$U+2;.66]GN;:2`/"G[M&92`2QQD<YRN:\R\"G'CK1L?\_(_D
M:OXEJCSM*%>*IRO?<^EZ***R/;"BBB@"MJ&H6NE:?/?7LRPVT"[I';L/ZD]`
M!R2<"O-_#AUGQYXN7Q-)-<6&B63&.TA5L&89Y4]B"0-YY'`49P2*VL75Q\3O
M%ZZ%82LGA_3WWW-Q'SYA&1D'ISRJ_P#`FY``'J=G9V^GV<-G:Q+%;PH$C1>B
MJ.@JMD<J;K2_NK\7_DBA<^';&=BR!X6/:,\?D?Z8K+O?#OV2UEN!=;@@SM,?
M7\<UU54=8_Y!%S_N5XF.RK!RI3J>S5TF]-.GD=T9RNE<X>MNP\/?;;2.X-UL
M#Y^41YQSCKFL0`DX`R:Z/0=4:^L(8--C\V--PEO&_P!2IR<JA_Y:-VX^4<Y;
M(VGY?(<'2Q5>4:T;I+SWNNQM6GRK0N6_ARQA8-)OF([.>/R']:UE4*H50``,
M`#M2C@`9S[T5]S0PM'#JU**1S.3>X4445T""O"OC-_R.MM_V#H__`$9+7NM>
M%?&;_D=;;_L'1_\`HR6KA\1Q9A_`?R._^$__`"3^T_ZZS?\`H9KS/XL,&\?7
M(!Y6&('Z[<_UJ?PKX]UCP=H<,4VE+=Z7.[FV=F,7S9.X!P"#R"<$9YZXQ7)Z
MMJ5YXDU^>^ECWW=Y*`L42YR>%1%'?@*/4U<5[USAKUXRP\::WT/>?AB"OP[T
MH$?\]3_Y%>M";Q1`F1#;2N1_?(7_`!JSX:TMM%\,Z=ISX\R"!5DVGC?C+8]M
MQ-8^O:6]O</=Q*3!(=S8_@;OGV/K_P#6KPLZKXNA1]KANF^E].Y[>&@E",9=
MD=5&Z31+(ARCJ&!]0:X_7;2*SU(K"`J.@?:.BDDCCVXJ.SUB\L8O*B=3'V5Q
MG;]*KN]QJ%WD[I9Y#T`Z_P#UJ^>S/-J..PT:<8/VEU\O3U.F%-Q=^ATGAAF.
MG2J3PLIQ[<"H/%7W+7ZM_2M72K'^S[%86(,A.YR.F3_D#\*RO%7W+7ZM_2O5
MQE*=')?9SW27YHB+O4N@\*_<NOJO]:T/$&F?VSX>U#3L#=<6[HA/0,1\I_`X
M/X5G^%?N77U7^M=%7;D7^X4_G^;(K).33/EOP_K4VA:A+=1%D=[6:`X'(+1D
M+^3[2?I70?"O2_[0\<VTA7,=E&]PP(X)`VK^.6!_X#67XXTS^R?&NJVJC$9G
M,R<8&UQO`'L-V/PKT;X*Z9Y6E:EJC#F>98$R/X4&21[$OC_@->Y)^[<^=PU-
MNNJ;VBV>I5\O^+O^1PUS_K^G_P#0S7U!7R_XN_Y'#7/^OZ;_`-#-33W.S,_@
MCZGTCH?_`"`--_Z]8O\`T`5\X>,?^1RUO_K]E_\`0C7T?H?_`"`--_Z]8O\`
MT$5X3\4=&ETOQI<W!C(MK_$\+XX)P`XSZAN<>C"BGN&81;HQ:Z'NN@L'\.Z8
MPZ&TB(_[X%?,WB3_`)&'6?\`K\N/_1C5VNA?%35M/T&UT2VTJ*[NXE$%M+N8
MD@<*OEJ,L0..&&>*X768;N#4[^._(-Z)7^T$8_UA)+=..N>G'I3@FF[G/BZ\
M*M./*?4UQ=0V.G2WEP^R""$RR-Z*HR3^0KYVUOQ!K?C[7XK<!RLLH6TL5;Y(
M_0GL6QG+'WZ#@>]^(;&;4_"FI6-N`9[BSDCC!.`6*D`?G7S;I&IW7A_7+?4(
M$VW-I(?W<JD<\JRL.HX)'J*4$;YA-IQB_A>YZG+\+]+T'P9JU]>LU[J<5A/(
MKDD1Q.(V(VKWQZMGD9`%>>^!?^1ZT;_KY'\C72ZW\1]=\7Z?<Z9I>E"U@^SR
M27GEOYS&(*2V6*@*N,CIDG`!R<'FO`O_`"/6C?\`7R/Y&J5[.YSU)4G5IJDM
M+GTO1116)[@5Q'Q1\0RZ+X8^R6C,+W46,$>S[P3'SD>^"%]<N".E=O7(7^CV
M_C*;0-=M[A<:=>/(JG[LBB0`CU#`QJ?J".^0T95N9P<8[LN^"O#,?A;PW!9;
M5^U./-NG'.Z0CD9]!P!],]2:Z*BL'7O&6A>'`RZA?H)P,BVB^>4\9'RCIGU.
M![T;E>Y2C;9(WJYKQ=XGTK1[%[2YN"]].`L-G`OF32$GC"CU[9QGZUR0\3^+
MO'DC0>&K/^RM+)*OJ$_WB.<X/0'V7)!Q\PKH]"\!6OA^-IK6?SM5ER9M1N4W
MR$GKLR?ESSZD]R>M95XITI)J]ULMS.-651_N]N[_`$[G-II-Y>()_$(^S6[#
M,>CPR'>X[&X<=N^P8SQGH17HFBMNT>V(5$4*55(U"JH!(``'0``#%93>%Y68
MLUZ&8G))C))/YU+#H-[;@+%JCHF<[5!`_+-?/X3Z[0K:4+4[644UY:MWU?F=
M?+"V]WW-^BBBOI#,****`"O"OC-_R.MM_P!@Z/\`]&2U[K7`>-OAS-XNUR+4
M8]4CM52V6#8T!<G#.V<[A_>_2JB[,Y<93E4I.,=Q_P`,;6WO?AO;VUW!%/`\
MLH>*5`RL/,/4'@UTNF^%M!TBY^T6&DVD$_.)5C&Y<]<$\C\*A\(>'W\,>'8=
M+>Y6Y:-W;S%38#N8GID^M;M)O4THT[0BI+5(****1L4WTJPD;<UI%GV7'\JG
MAMH+8$00QQ@]=B@9J6BLHT*4)<T8I/T0[L*BFMH+C'GPQR[>F]`V/SJ6BM)1
M4E:2NA$4-M!;Y\B&.+=UV(%S^52T441BHJT59`9U[X?T74[C[1?Z1874VT+Y
MD]LDC8'09(SCDU:L[*TTZV6VLK6&VMU)*Q0QA%&3DX`XZU/13%9;A63-X5\.
MW,\D\^@Z7++(Q=Y'LXV9F/)))')-:U%`-)[C8XTAB2*)%2-`%55&`H'0`=A4
M%_IUEJEL;:_M(+J`G/ES('&?7GO[U9HH"R>AE:7X:T319#)IVEVMO*1@R)&-
M^/3=UQQTI)_"WAZZGDGN-!TN:65BTDDEG&S.3U))')K6HH%R12M8``!@<"L;
M4?"?A_5KDW-]I%I-.WWI3&`S=N2.3T[ULT4#<5)6:*=KI&FV-F]G::?:P6T@
M(>&.%55\C!R`,'/O56#PMX>MIXYX-!TN*:-@R21V<:LK#H00.#6M10'*NP44
M44#"O';CPAX[\+ZK=?\`"*7+RV$TK2(J2Q@*#V9)3MW#ID9R`.G0%%-.QE5H
MJI:[M;L64\+?$K7@JZOK_P!A@/#JD@#X_P!V$!6^A:M[0OA/X=TG9+=HVI7`
MY)N`/+S[1C@CV;=111S,B.&IIW>K\]3NE540*JA548``P`*6BBD=`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
04`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
